[2]
. Alzheimer's Association. 2016 Alzheimer's disease facts and figures. Alzheimers Dement., 2016, 12, 459-509.
[3]
Hynd, M.R.; Scott, H.L.; Dodd, P.R. Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer’s disease. Neurochem. Int., 2004, 45, 583-595.
[4]
Aisen, P.S.; Andrieu, S.; Sampaio, C.; Carrillo, M.; Khachaturian, Z.S.; Dubois, B.; Feldman, H.H.; Petersen, R.C.; Siemers, E.; Doody, R.S.; Hendrix, S.B.; Grundman, M.; Schneider, L.S.; Schindler, R.J.; Salmon, E.; Potter, W.Z.; Thomas, R.G.; Salmon, D.; Donohue, M.; Bednar, M.M.; Touchon, J.; Vellas, B. Report of the task force on designing clinical trials in early (predementia) AD. Neurology, 2011, 76, 280-286.
[5]
van Dyck, C.H. Anti-amyloid-β monoclonal antibodies for Alzheimer’s disease: Pitfalls and promise. Biol. Psychiatry, 2018, 83, 311-319.
[6]
Hampel, H.; Mesulam, M.M.; Cuello, A.C.; Farlow, M.R.; Giacobini, E.; Grossberg, G.T.; Khachaturian, A.S.; Vergallo, A.; Cavedo, E.; Snyder, P.J.; Khachaturian, Z.S. The cholinergic system in the pathophysiology and treatment of Alzheimer’s disease. Brain, 2018, 141, 1917-1933.
[7]
Yin, F.; Sancheti, H.; Patil, I.; Cadenas, E. Energy metabolism and inflammation in brain aging and Alzheimer’s disease. Free Radic. Biol. Med., 2016, 100, 108-122.
[8]
Francis, P.T. Altered glutamate neurotransmission and behaviour in dementia: Evidence from studies of memantine. Curr. Mol. Pharmacol., 2009, 2, 77-82.
[9]
Chapman, C.D.; Schioth, H.B.; Grillo, C.A.; Benedict, C. Intranasal insulin in Alzheimer’s disease: Food for thought. Neuropharmacology, 2018, 136, 196-201.
[10]
Guo, L.; Tian, J.; Du, H. Mitochondrial dysfunction and synaptic transmission failure in Alzheimer’s disease. J. Alzheimers Dis., 2017, 57, 1071-1086.
[11]
Chandra, V.; Pandav, R.; Dodge, H.H.; Johnston, J.M.; Belle, S.H.; DeKosky, S.T.; Ganguli, M. Incidence of Alzheimer’s disease in a rural community in India: The Indo-US study. Neurology, 2001, 57, 985-989.
[12]
Nalli, M.; Ortar, G.; Schiano, M.A.; Di, M.V.; De, P.L. Effects of curcumin and curcumin analogues on TRP channels. Fitoterapia, 2017, 122, 126-131.
[13]
Yamamoto, S.; Wajima, T.; Hara, Y.; Nishida, M.; Mori, Y. Transient receptor potential channels in Alzheimer’s disease. Biochim. Biophys. Acta, 2007, 1772, 958-967.
[14]
Kaneko, Y.; Szallasi, A. Transient receptor potential (TRP) channels: A clinical perspective. Br. J. Pharmacol., 2014, 171, 2474-2507.
[15]
Iannuzzi, C.; Borriello, M.; Irace, G.; Cammarota, M.; Di, M.A.; Sirangelo, I. Vanillin affects amyloid aggregation and non-enzymatic glycation in human insulin. Sci. Rep., 2017, 7, 15086.
[16]
Yeo, E.T.Y.; Wong, K.W.L.; See, M.L.; Wong, K.Y.; Gan, S.Y.; Chan, E.W.L. Piper sarmentosum Roxb. confers neuroprotection on β-amyloid (Aβ)-induced microglia-mediated neuroinflammation and attenuates tau hyperphosphorylation in SH-SY5Y cells. J. Ethnopharmacol., 2018, 217, 187-194.
[17]
Bigford, G.E.; Del, R.G. Supplemental substances derived from foods as adjunctive therapeutic agents for treatment of neurodegenerative diseases and disorders. Adv. Nutr., 2014, 5, 394-403.
[18]
Davinelli, S.; Sapere, N.; Zella, D.; Bracale, R.; Intrieri, M.; Scapagnini, G. Pleiotropic protective effects of phytochemicals in Alzheimer’s disease. Oxid. Med. Cell. Longev., 2012, 2012, 386527.
[19]
Calcul, L.; Zhang, B.; Jinwal, U.K.; Dickey, C.A.; Baker, B.J. Natural products as a rich source of tau-targeting drugs for Alzheimer’s disease. Future Med. Chem., 2012, 4, 1751-1761.
[20]
Hamaguchi, T.; Ono, K.; Yamada, M. REVIEW: Curcumin and Alzheimer’s disease. CNS Neurosci. Ther., 2010, 16, 285-297.
[21]
Wang, Z.Y.; Liu, J.G.; Li, H.; Yang, H.M. Pharmacological effects of active components of chinese herbal medicine in the treatment of Alzheimer’s disease: A Review. Am. J. Chin. Med., 2016, 44, 1525-1541.
[22]
Shytle, R.D.; Tan, J.; Bickford, P.C.; Rezai-Zadeh, K.; Hou, L.; Zeng, J.; Sanberg, P.R.; Sanberg, C.D.; Alberte, R.S.; Fink, R.C.; Roschek, B., Jr Optimized turmeric extract reduces β-amyloid and phosphorylated Tau protein burden in Alzheimer’s transgenic mice. Curr. Alzheimer Res., 2012, 9, 500-506.
[23]
Huang, H.C.; Zheng, B.W.; Guo, Y.; Zhao, J.; Zhao, J.Y.; Ma, X.W.; Jiang, Z.F. Antioxidative and neuroprotective effects of curcumin in an Alzheimer’s disease rat model co-treated with intracerebroventricular streptozotocin and subcutaneous D-galactose. J. Alzheimers Dis., 2016, 52, 899-911.
[24]
Tello-Franco, V.; Lozada-Garcia, M.C.; Soriano-Garcia, M. Experimental and computational studies on the inhibition of acetylcholinesterase by curcumin and some of its derivatives. Curr. Comput. Aided Drug Des., 2013, 9, 289-298.
[25]
Mithu, V.S.; Sarkar, B.; Bhowmik, D.; Das, A.K.; Chandrakesan, M.; Maiti, S.; Madhu, P.K. Curcumin alters the salt bridge-containing turn region in amyloid β1-42 aggregates. J. Biol. Chem., 2014, 289, 11122-11131.
[26]
Chandra, B.; Mithu, V.S.; Bhowmik, D.; Das, A.K.; Sahoo, B.; Maiti, S.; Madhu, P.K. Curcumin dictates divergent fates for the central salt bridges in amyloid-β40 and amyloid- β42. Biophys. J., 2017, 112, 1597-1608.
[27]
Xiao, Z.; Zhang, A.; Lin, J.; Zheng, Z.; Shi, X.; Di, W.; Qi, W.; Zhu, Y.; Zhou, G.; Fang, Y. Telomerase: A target for therapeutic effects of curcumin and a curcumin derivative in Aβ1-42 insult in vitro. PLoS One, 2014, 9, e101251.
[28]
Zhang, Y.; Yong, H.Y.; Shi, X.T.; Zhou, J.; Ma, Q.; Lian, Q.Q.; Cao, H.; Li, J. Protective effect of curcumin against Aβ25-35-induced neurotoxicity in differentiated PC12 cells. Zhonghua Yi Xue Za Zhi, 2013, 93, 2826-2829.
[29]
Reddy, P.H.; Manczak, M.; Yin, X.; Grady, M.C.; Mitchell, A.; Kandimalla, R.; Kuruva, C.S. Protective effects of a natural product, curcumin, against amyloid β induced mitochondrial and synaptic toxicities in Alzheimer’s disease. J. Investig. Med., 2016, 64, 1220-1234.
[30]
Meng, J.; Li, Y.; Camarillo, C.; Yao, Y.; Zhang, Y.; Xu, C.; Jiang, L. The anti-tumor histone deacetylase inhibitor SAHA and the natural flavonoid curcumin exhibit synergistic neuroprotection against amyloid-β toxicity. PLoS One, 2014, 9, e85570.
[31]
Uguz, A.C.; Oz, A.; Naziroglu, M. Curcumin inhibits apoptosis by regulating intracellular calcium release, reactive oxygen species and mitochondrial depolarization levels in SH-SY5Y neuronal cells. J. Recept. Signal Transduct. Res., 2016, 36, 395-401.
[32]
Khan, S.; Ahmad, K.; Alshammari, E.M.; Adnan, M.; Baig, M.H.; Lohani, M.; Somvanshi, P.; Haque, S. Implication of caspase-3 as a common therapeutic target for multineurodegenerative disorders and its inhibition using nonpeptidyl natural compounds. BioMed Res. Int., 2015, 2015, 379817.
[33]
Sun, J.; Zhang, X.; Wang, C.; Teng, Z.; Li, Y. Curcumin decreases hyperphosphorylation of tau by down-regulating caveolin-1/GSK-3β in N2a/APP695swe cells and APP/PS1 double transgenic Alzheimer’s disease mice. Am. J. Chin. Med., 2017, 45, 1667-1682.
[34]
Widyowati, R.; Agil, M. Chemical constituents and bioactivities of several Indonesian plants typically used in Jamu. Chem. Pharm. Bull. (Tokyo), 2018, 66, 506-518.
[35]
Ahmed, T.; Gilani, A.H. Therapeutic potential of turmeric in Alzheimer’s disease: Curcumin or curcuminoids? Phytother. Res., 2014, 28, 517-525.
[36]
Kalaycioglu, Z.; Gazioglu, I.; Erim, F.B. Comparison of antioxidant, anticholinesterase, and antidiabetic activities of three curcuminoids isolated from Curcuma longa L. Nat. Prod. Res., 2017, 31, 2914-2917.
[37]
Ahmed, T.; Gilani, A.H. Inhibitory effect of curcuminoids on acetylcholinesterase activity and attenuation of scopolamine-induced amnesia may explain medicinal use of turmeric in Alzheimer’s disease. Pharmacol. Biochem. Behav., 2009, 91, 554-559.
[38]
Jiang, Y.; Gao, H.; Turdu, G. Traditional Chinese medicinal herbs as potential AChE inhibitors for anti-Alzheimer’s disease: A review. Bioorg. Chem., 2017, 75, 50-61.
[39]
Barbara, R.; Belletti, D.; Pederzoli, F.; Masoni, M.; Keller, J.; Ballestrazzi, A.; Vandelli, M.A.; Tosi, G.; Grabrucker, A.M. Novel Curcumin loaded nanoparticles engineered for blood-brain barrier crossing and able to disrupt Aβ aggregates. Int. J. Pharm., 2017, 526, 413-424.
[40]
Liu, Z.; Fang, L.; Zhang, H.; Gou, S.; Chen, L. Design, synthesis and biological evaluation of multifunctional tacrine-curcumin hybrids as new cholinesterase inhibitors with metal ions-chelating and neuroprotective property. Bioorg. Med. Chem., 2017, 25, 2387-2398.
[41]
Yan, J.; Hu, J.; Liu, A.; He, L.; Li, X.; Wei, H. Design, synthesis, and evaluation of multitarget-directed ligands against Alzheimer’s disease based on the fusion of donepezil and curcumin. Bioorg. Med. Chem., 2017, 25, 2946-2955.
[42]
Feng, H.L.; Fan, H.; Dang, H.Z.; Chen, X.P.; Ren, Y.; Yang, J.D.; Wang, P.W. Neuroprotective effect of curcumin to Aβ of double transgenic mice with Alzheimer’s disease. Zhongguo Zhongyao Zazhi, 2014, 39, 3846-3849.
[44]
Ghosh, S.; Basak, P.; Dutta, S.; Chowdhury, S.; Sil, P.C. New insights into the ameliorative effects of ferulic acid in pathophysiological conditions. Food Chem. Toxicol., 2017, 103, 41-55.
[45]
Yanagisawa, D.; Ibrahim, N.F.; Taguchi, H.; Morikawa, S.; Hirao, K.; Shirai, N.; Sogabe, T.; Tooyama, I. Curcumin derivative with the substitution at C-4 position, but not curcumin, is effective against amyloid pathology in APP/PS1 mice. Neurobiol. Aging, 2015, 36, 201-210.
[46]
Quitschke, W.W.; Steinhauff, N.; Rooney, J. The effect of cyclodextrin-solubilized curcuminoids on amyloid plaques in Alzheimer transgenic mice: brain uptake and metabolism after intravenous and subcutaneous injection. Alzheimers Res. Ther., 2013, 5, 16.
[47]
Wang, P.; Su, C.; Li, R.; Wang, H.; Ren, Y.; Sun, H.; Yang, J.; Sun, J.; Shi, J.; Tian, J.; Jiang, S. Mechanisms and effects of curcumin on spatial learning and memory improvement in APPswe/PS1dE9 mice. J. Neurosci. Res., 2014, 92, 218-231.
[48]
Wang, C.; Zhang, X.; Teng, Z.; Zhang, T.; Li, Y. Downregulation of PI3K/Akt/mTOR signaling pathway in curcumin-induced autophagy in APP/PS1 double transgenic mice. Eur. J. Pharmacol., 2014, 740, 312-320.
[49]
Tai, Y.H.; Lin, Y.Y.; Wang, K.C.; Chang, C.L.; Chen, R.Y.; Wu, C.C.; Cheng, I.H. Curcuminoid submicron particle ameliorates cognitive deficits and decreases amyloid pathology in Alzheimer’s disease mouse model. Oncotarget, 2018, 9, 10681-10697.
[50]
Maiti, P.; Hall, T.C.; Paladugu, L.; Kolli, N.; Learman, C.; Rossignol, J.; Dunbar, G.L. A comparative study of dietary curcumin, nanocurcumin, and other classical amyloid-binding dyes for labeling and imaging of amyloid plaques in brain tissue of 5x-familial Alzheimer’s disease mice. Histochem. Cell Biol., 2016, 146, 609-625.
[51]
Song, J.X.; Sun, Y.R.; Peluso, I.; Zeng, Y.; Yu, X.; Lu, J.H.; Xu, Z.; Wang, M.Z.; Liu, L.F.; Huang, Y.Y.; Chen, L.L.; Durairajan, S.S.; Zhang, H.J.; Zhou, B.; Zhang, H.Q.; Lu, A.; Ballabio, A.; Medina, D.L.; Guo, Z.; Li, M. A novel curcumin analog binds to and activates TFEB in vitro and in vivo independent of MTOR inhibition. Autophagy, 2016, 12, 1372-1389.
[52]
He, Y.; Wang, P.; Wei, P.; Feng, H.; Ren, Y.; Yang, J.; Rao, Y.; Shi, J.; Tian, J. Effects of curcumin on synapses in APPswe/PS1dE9 mice. Int. J. Immunopathol. Pharmacol., 2016, 29, 217-225.
[53]
Huang, H.C.; Zheng, B.W.; Guo, Y.; Zhao, J.; Zhao, J.Y.; Ma, X.W.; Jiang, Z.F. Antioxidative and neuroprotective effects of curcumin in an Alzheimer’s disease rat model co-treated with intracerebroventricular streptozotocin and subcutaneous D-galactose. J. Alzheimers Dis., 2016, 52, 899-911.
[54]
Samy, D.M.; Ismail, C.A.; Nassra, R.A.; Zeitoun, T.M.; Nomair, A.M. Downstream modulation of extrinsic apoptotic pathway in streptozotocin-induced Alzheimer’s dementia in rats: Erythropoietin versus curcumin. Eur. J. Pharmacol., 2016, 770, 52-60.
[55]
Bassani, T.B.; Turnes, J.M.; Moura, E.L.R.; Bonato, J.M.; Coppola-Segovia, V.; Zanata, S.M.; Oliveira, R.M.M.W.; Vital, M.A.B.F. Effects of curcumin on short-term spatial and recognition memory, adult neurogenesis and neuroinflammation in a streptozotocin-induced rat model of dementia of Alzheimer’s type. Behav. Brain Res., 2017, 335, 41-54.
[56]
Kuo, Y.C.; Lin, C.Y.; Li, J.S.; Lou, Y.I. Wheat germ agglutinin-conjugated liposomes incorporated with cardiolipin to improve neuronal survival in Alzheimer’s disease treatment. Int. J. Nanomedicine, 2017, 12, 1757-1774.
[57]
Teixeira, C.C.; Mendonca, L.M.; Bergamaschi, M.M.; Queiroz, R.H.; Souza, G.E.; Antunes, L.M.; Freitas, L.A. Microparticles containing curcumin solid dispersion: Stability, bioavailability and anti-inflammatory activity. AAPS PharmSciTech, 2016, 17, 252-261.
[58]
Liu, Z.J.; Li, Z.H.; Liu, L.; Tang, W.X.; Wang, Y.; Dong, M.R.; Xiao, C. Curcumin attenuates β-amyloid-induced neuroinflammation via activation of peroxisome proliferator-activated receptor-γ function in a rat model of Alzheimer’s disease. Front. Pharmacol., 2016, 7, 261.
[59]
Zaky, A.; Bassiouny, A.; Farghaly, M.; El-Sabaa, B.M. A combination of resveratrol and curcumin is effective against aluminum chloride-induced neuroinflammation in rats. J. Alzheimers Dis., 2017, 60, S221-S235.
[60]
Prior, M.; Goldberg, J.; Chiruta, C.; Farrokhi, C.; Kopynets, M.; Roberts, A.J.; Schubert, D. Selecting for neurogenic potential as an alternative for Alzheimer’s disease drug discovery. Alzheimers Dement., 2016, 12, 678-686.
[61]
Feng, H.L.; Dang, H.Z.; Fan, H.; Chen, X.P.; Rao, Y.X.; Ren, Y.; Yang, J.D.; Shi, J.; Wang, P.W.; Tian, J.Z. Curcumin ameliorates insulin signalling pathway in brain of Alzheimer’s disease transgenic mice. Int. J. Immunopathol. Pharmacol., 2016, 29, 734-741.
[62]
Dang, H.Z.; Li, R.S.; Wang, H.; Ren, Y.; Sun, H.Y.; Yang, J.D.; Wang, P.W. Effects of curcumin on expression of PI3K and p-pI3K in hippocampus of AD mice. Zhongguo Zhongyao Zazhi, 2013, 38, 1295-1299.
[63]
Agrawal, R.; Mishra, B.; Tyagi, E.; Nath, C.; Shukla, R. Effect of curcumin on brain insulin receptors and memory functions in STZ (ICV) induced dementia model of rat. Pharmacol. Res., 2010, 61, 247-252.
[64]
Wang, P.; Su, C.; Feng, H.; Chen, X.; Dong, Y.; Rao, Y.; Ren, Y.; Yang, J.; Shi, J.; Tian, J.; Jiang, S. Curcumin regulates insulin pathways and glucose metabolism in the brains of APPswe/PS1dE9 mice. Int. J. Immunopathol. Pharmacol., 2017, 30, 25-43.
[65]
Moore, T.L.; Bowley, B.; Shultz, P.; Calderazzo, S.; Shobin, E.; Killiany, R.J.; Rosene, D.L.; Moss, M.B. Chronic curcumin treatment improves spatial working memory but not recognition memory in middle-aged rhesus monkeys. Geroscience, 2017, 39, 571-584.
[66]
Zhang, L.; Fang, Y.; Xu, Y.; Lian, Y.; Xie, N.; Wu, T.; Zhang, H.; Sun, L.; Zhang, R.; Wang, Z. Curcumin improves amyloid β-peptide1-42 induced spatial memory deficits through BDNF-ERK signaling pathway. PLoS One, 2015, 10, e0131525.
[67]
Yin, H.L.; Wang, Y.L.; Li, J.F.; Han, B.; Zhang, X.X.; Wang, Y.T.; Geng, S. Effects of curcumin on hippocampal expression of NgR and axonal regeneration in Aβ-induced cognitive disorder rats. Genet. Mol. Res., 2014, 13, 2039-2047.
[68]
Barber, T.A.; Edris, E.M.; Levinsky, P.J.; Williams, J.M.; Brouwer, A.R.; Gessay, S.A. Amelioration of scopolamine-induced amnesia by phosphatidylserine and curcumin in the day-old chick. Behav. Pharmacol., 2016, 27, 536-541.
[69]
Head, E.; Murphey, H.L.; Dowling, A.L.; McCarty, K.L.; Bethel, S.R.; Nitz, J.A.; Pleiss, M.; Vanrooyen, J.; Grossheim, M.; Smiley, J.R.; Murphy, M.P.; Beckett, T.L.; Pagani, D.; Bresch, F.; Hendrix, C. A combination cocktail improves spatial attention in a canine model of human aging and Alzheimer’s disease. J. Alzheimers Dis., 2012, 32, 1029-1042.
[70]
Jia, T.; Sun, Z.; Lu, Y.; Gao, J.; Zou, H.; Xie, F.; Zhang, G.; Xu, H.; Sun, D.; Yu, Y.; Zhong, Y. A dual brain-targeting curcumin-loaded polymersomes ameliorated cognitive dysfunction in intrahippocampal amyloid-β1-42-injected mice. Int. J. Nanomedicine, 2016, 11, 3765-3775.
[71]
Zheng, K.; Dai, X.; Xiao, N.; Wu, X.; Wei, Z.; Fang, W.; Zhu, Y.; Zhang, J.; Chen, X. Curcumin ameliorates memory decline via inhibiting BACE1 expression and β-amyloid pathology in 5xFAD transgenic mice. Mol. Neurobiol., 2017, 54, 1967-1977.
[72]
Wang, Y.; Yin, H.; Li, J.; Zhang, Y.; Han, B.; Zeng, Z.; Qiao, N.; Cui, X.; Lou, J.; Li, J. Amelioration of β-amyloid-induced cognitive dysfunction and hippocampal axon degeneration by curcumin is associated with suppression of CRMP-2 hyperphosphorylation. Neurosci. Lett., 2013, 557 Pt B, 112-117.
[73]
Sundaram, J.R.; Poore, C.P.; Sulaimee, N.H.B.; Pareek, T.; Cheong, W.F.; Wenk, M.R.; Pant, H.C.; Frautschy, S.A.; Low, C.M.; Kesavapany, S. Curcumin ameliorates neuroinflammation, neurodegeneration, and memory deficits in p25 transgenic mouse model that bears hallmarks of Alzheimer’s disease. J. Alzheimers Dis., 2017, 60, 1429-1442.
[74]
McClure, R.; Ong, H.; Janve, V.; Barton, S.; Zhu, M.; Li, B.; Dawes, M.; Jerome, W.G.; Anderson, A.; Massion, P.; Gore, J.C.; Pham, W. Aerosol delivery of curcumin reduced amyloid-β deposition and improved cognitive performance in a transgenic model of Alzheimer’s disease. J. Alzheimers Dis., 2017, 55, 797-811.
[76]
Elmegeed, G.A.; Ahmed, H.H.; Hashash, M.A.; Abd-Elhalim, M.M.; El-kady, D.S. Synthesis of novel steroidal curcumin derivatives as anti-Alzheimer’s disease candidates: Evidences-based on in vivo study. Steroids, 2015, 101, 78-89.
[77]
Tiwari, S.K.; Agarwal, S.; Seth, B.; Yadav, A.; Nair, S.; Bhatnagar, P.; Karmakar, M.; Kumari, M.; Chauhan, L.K.; Patel, D.K.; Srivastava, V.; Singh, D.; Gupta, S.K.; Tripathi, A.; Chaturvedi, R.K.; Gupta, K.C. Curcumin-loaded nanoparticles potently induce adult neurogenesis and reverse cognitive deficits in Alzheimer’s disease model via canonical Wnt/ β-catenin pathway. ACS Nano, 2014, 8, 76-103.
[78]
Chojnacki, J.E.; Liu, K.; Saathoff, J.M.; Zhang, S. Bivalent ligands incorporating curcumin and diosgenin as multifunctional compounds against Alzheimer’s disease. Bioorg. Med. Chem., 2015, 23, 7324-7331.
[79]
Liu, K.; Chojnacki, J.E.; Wade, E.E.; Saathoff, J.M.; Lesnefsky, E.J.; Chen, Q.; Zhang, S. Bivalent compound 17MN exerts neuroprotection through Interaction at multiple sites in a cellular model of Alzheimer’s disease. J. Alzheimers Dis., 2015, 47, 1021-1033.
[80]
Chojnacki, J.E.; Liu, K.; Yan, X.; Toldo, S.; Selden, T.; Estrada, M.; Rodriguez-Franco, M.I.; Halquist, M.S.; Ye, D.; Zhang, S. Discovery of 5-(4-hydroxyphenyl)-3-oxo-pentanoic acid [2-(5-methoxy-1H-indol-3-yl)-ethyl]-amide as a neuroprotectant for Alzheimer’s disease by hybridization of curcumin and melatonin. ACS Chem. Neurosci., 2014, 5, 690-699.
[81]
Fang, L.; Gou, S.; Liu, X.; Cao, F.; Cheng, L. Design, synthesis and anti-Alzheimer properties of dimethylaminomethyl-substituted curcumin derivatives. Bioorg. Med. Chem. Lett., 2014, 24, 40-43.
[82]
Kuo, Y.C.; Lin, C.C. Rescuing apoptotic neurons in Alzheimer’s disease using wheat germ agglutinin-conjugated and cardiolipin-conjugated liposomes with encapsulated nerve growth factor and curcumin. Int. J. Nanomedicine, 2015, 10, 2653-2672.
[83]
Tang, M.; Taghibiglou, C. The mechanisms of action of curcumin in Alzheimer’s disease. J. Alzheimers Dis., 2017, 58, 1003-1016.
[84]
Pluta, R.; Bogucka-Kocka, A.; Ulamek-Koziol, M.; Furmaga-Jablonska, W.; Januszewski, S.; Brzozowska, J.; Jablonski, M.; Kocki, J. Neurogenesis and neuroprotection in postischemic brain neurodegeneration with Alzheimer phenotype: is there a role for curcumin? Folia Neuropathol., 2015, 53, 89-99.
[85]
Goozee, K.G.; Shah, T.M.; Sohrabi, H.R.; Rainey-Smith, S.R.; Brown, B.; Verdile, G.; Martins, R.N. Examining the potential clinical value of curcumin in the prevention and diagnosis of Alzheimer’s disease. Br. J. Nutr., 2016, 115, 449-465.
[86]
Nelson, K.M.; Dahlin, J.L.; Bisson, J.; Graham, J.; Pauli, G.F.; Walters, M.A. The essential medicinal chemistry of curcumin. J. Med. Chem., 2017, 60, 1620-1637.
[87]
Bahadori, F.; Demiray, M. A realistic view on “The essential medicinal chemistry of curcumin”. ACS Med. Chem. Lett., 2017, 8, 893-896.
[88]
Heger, M. Drug screening: Don’t discount all curcumin trial data. Nature, 2017, 543, 40.
[89]
Baum, L.; Lam, C.W.; Cheung, S.K.; Kwok, T.; Lui, V.; Tsoh, J.; Lam, L.; Leung, V.; Hui, E.; Ng, C.; Woo, J.; Chiu, H.F.; Goggins, W.B.; Zee, B.C.; Cheng, K.F.; Fong, C.Y.; Wong, A.; Mok, H.; Chow, M.S.; Ho, P.C.; Ip, S.P.; Ho, C.S.; Yu, X.W.; Lai, C.Y.; Chan, M.H.; Szeto, S.; Chan, I.H.; Mok, V. Six-month randomized, placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with Alzheimer disease. J. Clin. Psychopharmacol., 2008, 28, 110-113.
[90]
Ringman, J.M.; Frautschy, S.A.; Teng, E.; Begum, A.N.; Bardens, J.; Beigi, M.; Gylys, K.H.; Badmaev, V.; Heath, D.D.; Apostolova, L.G.; Porter, V.; Vanek, Z.; Marshall, G.A.; Hellemann, G.; Sugar, C.; Masterman, D.L.; Montine, T.J.; Cummings, J.L.; Cole, G.M. Oral curcumin for Alzheimer’s disease: tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study. Alzheimers Res. Ther., 2012, 4, 43.
[91]
Hishikawa, N.; Takahashi, Y.; Amakusa, Y.; Tanno, Y.; Tuji, Y.; Niwa, H.; Murakami, N.; Krishna, U.K. Effects of turmeric on Alzheimer’s disease with behavioral and psychological symptoms of dementia. Ayu, 2012, 33, 499-504.
[92]
Cox, K.H.; Pipingas, A.; Scholey, A.B. Investigation of the effects of solid lipid curcumin on cognition and mood in a healthy older population. J. Psychopharmacol., 2015, 29, 642-651.
[93]
Gota, V.S.; Maru, G.B.; Soni, T.G.; Gandhi, T.R.; Kochar, N.; Agarwal, M.G. Safety and pharmacokinetics of a solid lipid curcumin particle formulation in osteosarcoma patients and healthy volunteers. J. Agric. Food Chem., 2010, 58, 2095-2099.
[94]
Rainey-Smith, S.R.; Brown, B.M.; Sohrabi, H.R.; Shah, T.; Goozee, K.G.; Gupta, V.B.; Martins, R.N. Curcumin and cognition: a randomised, placebo-controlled, double-blind study of community-dwelling older adults. Br. J. Nutr., 2016, 115, 2106-2113.
[95]
Small, G.W.; Siddarth, P.; Li, Z.; Miller, K.J.; Ercoli, L.; Emerson, N.D.; Martinez, J.; Wong, K.P.; Liu, J.; Merrill, D.A.; Chen, S.T.; Henning, S.M.; Satyamurthy, N.; Huang, S.C.; Heber, D.; Barrio, J.R. Memory and brain amyloid and Tau effects of a bioavailable form of curcumin in non-demented adults: A double-blind, placebo-controlled 18-month trial. Am. J. Geriatr. Psychiatry, 2018, 26, 266-277.
[96]
Jankun, J.; Wyganowska-Swiatkowska, M.; Dettlaff, K.; Jelinska, A.; Surdacka, A.; Watrobska-Swietlikowska, D.; Skrzypczak-Jankun, E. Determining whether curcumin degradation/condensation is actually bioactivation.(Review) Int. J. Mol. Med., 2016, 37, 1151-1158.
[97]
Martin, R.C.; Aiyer, H.S.; Malik, D.; Li, Y. Effect on pro-inflammatory and antioxidant genes and bioavailable distribution of whole turmeric vs curcumin: Similar root but different effects. Food Chem. Toxicol., 2012, 50, 227-231.
[98]
Sasaki, H.; Sunagawa, Y.; Takahashi, K.; Imaizumi, A.; Fukuda, H.; Hashimoto, T.; Wada, H.; Katanasaka, Y.; Kakeya, H.; Fujita, M.; Hasegawa, K.; Morimoto, T. Innovative preparation of curcumin for improved oral bioavailability. Biol. Pharm. Bull., 2011, 34, 660-665.
[99]
Braga, M.E.; Leal, P.F.; Carvalho, J.E.; Meireles, M.A. Comparison of yield, composition, and antioxidant activity of turmeric (Curcuma longa L.) extracts obtained using various techniques. J. Agric. Food Chem., 2003, 51, 6604-6611.
[100]
Sgarbossa, A.; Giacomazza, D. di, C.M. Ferulic acid: A hope for Alzheimer’s disease therapy from plants. Nutrients, 2015, 7, 5764-5782.
[101]
Moran, M.M.; Xu, H.; Clapham, D.E. TRP ion channels in the nervous system. Curr. Opin. Neurobiol., 2004, 14, 362-369.
[102]
Venkatachalam, K.; Montell, C. TRP channels. Annu. Rev. Biochem., 2007, 76, 387-417.
[103]
Wu, L.J.; Sweet, T.B.; Clapham, D.E. International Union of Basic and Clinical Pharmacology. LXXVI. Current progress in the mammalian TRP ion channel family. Pharmacol. Rev., 2010, 62, 381-404.
[104]
Nilius, B. Transient Receptor Potential (TRP) channels in the brain: the good and the ugly 2012, 20(3), 343-355.
[106]
Bosson, A.; Paumier, A.; Boisseau, S.; Jacquier-Sarlin, M.; Buisson, A.; Albrieux, M. TRPA1 channels promote astrocytic Ca2+ hyperactivity and synaptic dysfunction mediated by oligomeric forms of amyloid-β peptide. Mol. Neurodegener., 2017, 12, 53.
[107]
Zhang, L.; Fang, Y.; Cheng, X.; Lian, Y.; Xu, H.; Zeng, Z.; Zhu, H. TRPML1 participates in the progression of Alzheimer’s disease by regulating the PPARgamma/AMPK/Mtor signalling pathway. Cell. Physiol. Biochem., 2017, 43, 2446-2456.
[109]
Leamy, A.W.; Shukla, P.; McAlexander, M.A.; Carr, M.J.; Ghatta, S. Curcumin ((E, E)-1, 7-bis(4-hydroxy-3-methoxyphenyl)-1, 6-heptadiene-3, 5-dione) activates and desensitizes the nociceptor ion channel TRPA1. Neurosci. Lett., 2011, 503, 157-162.
[110]
Zhang, L.; Fang, Y.; Cheng, X.; Lian, Y.J.; Xu, H.L.; Zeng, Z.S.; Zhu, H.C. Curcumin exerts effects on the pathophysiology of Alzheimer’s disease by regulating PI(3, 5)P2 and Transient Receptor Potential Mucolipin-1 expression. Front. Neurol., 2017, 8, 531.
[111]
Oz, A.; Celik, O. Curcumin inhibits oxidative stress-induced TRPM2 channel activation, calcium ion entry and apoptosis values in SH-SY5Y neuroblastoma cells: Involvement of transfection procedure. Mol. Membr. Biol., 2016, 33, 76-88.
[112]
Obi, S.; Nakajima, T.; Hasegawa, T.; Kikuchi, H.; Oguri, G.; Takahashi, M.; Nakamura, F.; Yamasoba, T.; Sakuma, M.; Toyoda, S.; Tei, C.; Inoue, T. Heat induces interleukin-6 in skeletal muscle cells via TRPV1/PKC/CREB pathways. J. Appl. Physiol., 2017, 122, 683-694.
[113]
Zhang, X.; Chen, Q.; Wang, Y.; Peng, W.; Cai, H. Effects of curcumin on ion channels and transporters. Front. Physiol., 2014, 5, 94.
[114]
Wu, Y.; Qin, D.; Yang, H.; Fu, H. Evidence for the participation of acid-sensing ion channels (ASICs) in the antinociceptive effect of curcumin in a formalin-induced orofacial inflammatory model. Cell. Mol. Neurobiol., 2017, 37, 635-642.
[115]
Du, J.; Reznikov, L.R.; Price, M.P.; Zha, X.M.; Lu, Y.; Moninger, T.O.; Wemmie, J.A.; Welsh, M.J. Protons are a neurotransmitter that regulates synaptic plasticity in the lateral amygdala. Proc. Natl. Acad. Sci. USA, 2014, 111, 8961-8966.
[116]
Storozhuk, M.; Kondratskaya, E.; Nikolaenko, L.; Krishtal, O. A modulatory role of ASICs on GABAergic synapses in rat hippocampal cell cultures. Mol. Brain, 2016, 9, 90.
[117]
Gonzales, E.B.; Sumien, N. Acidity and acid-sensing ion channels in the normal and Alzheimer’s disease brain. J. Alzheimers Dis., 2017, 57, 1137-1144.
[118]
Stohs, S.J.; Ji, J.; Bucci, L.R.; Preuss, H.G. A comparative pharmacokinetic assessment of a novel highly bioavailable curcumin formulation with 95% curcumin: A randomized, double-blind, crossover study. J. Am. Coll. Nutr., 2018, 37, 51-59.
[120]
Li, S.; Yuan, W.; Deng, G.; Wang, P.; Yang, P.; Aggarwal, B.B. Chemical composition and product quality control of turmeric (Curcuma longa L.). Pharmaceutical Crops, 2011, 2, 28-54.
[121]
Srinivas, L.; Shalini, V.K.; Shylaja, M. Turmerin: A water soluble antioxidant peptide from turmeric (Curcuma longa). Arch. Biochem. Biophys., 1992, 292, 617-623.
[122]
Lekshmi, P.C.; Arimboor, R.; Raghu, K.G.; Menon, A.N. Turmerin, the antioxidant protein from turmeric (Curcuma longa) exhibits antihyperglycaemic effects. Nat. Prod. Res., 2012, 26, 1654-1658.
[123]
Antony, B.; Merina, B.; Iyer, V.S.; Judy, N.; Lennertz, K.; Joyal, S. A pilot cross-over study to evaluate human oral bioavailability of BCM-95CG (Biocurcumax), a novel bioenhanced preparation of curcumin. Indian J. Pharm. Sci., 2008, 70, 445-449.
[124]
Sunagawa, Y.; Hirano, S.; Katanasaka, Y.; Miyazaki, Y.; Funamoto, M.; Okamura, N.; Hojo, Y.; Suzuki, H.; Doi, O.; Yokoji, T.; Morimoto, E.; Takashi, T.; Ozawa, H.; Imaizumi, A.; Ueno, M.; Kakeya, H.; Shimatsu, A.; Wada, H.; Hasegawa, K.; Morimoto, T. Colloidal submicron-particle curcumin exhibits high absorption efficiency-a double-blind, 3-way crossover study. J. Nutr. Sci. Vitaminol. (Tokyo), 2015, 61, 37-44.
